In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fact File: Coronavirus Medtech And Diagnostic Updates

Executive Summary

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

You may also be interested in...



European Commission Recommends Regulatory Midway For COVID-19 Products

The EU is addressing the regulatory obstacles that threaten to reduce the speed at which vital products needed to treat COVID-19 are produced.

Ventilator Firms Across Europe Ramp Up Production To Meet ‘Unprecedented’ Demand

Production of ventilators is up by tens of thousands of units across Europe, but the supply chain is likely to come under strain with further expansion. 

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV124479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel